Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

Phase 2 Unknown 45 enrolled Anhui Chest Hospital

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The trial was a randomized, open-label, multicenter Phase II study of patients with advanced or metastatic NSCLC who don't harbor driver genes. The aim is to explore the efficacy and safety of Envafolimab Combined With Endostar/S-1 in second-line treatment of advanced non-small cell lung cancer.

Timeline

Start: 2022-09-18
Primary completion: 2023-09-18
Completion: 2023-09-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Endostar	Protein / enzyme biologic	210 mg	—
Subject	Envafolimab	Monoclonal antibody	300 mg	Subcutaneous
Subject	S-1	Small molecule	40 mg	—

Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

Summary

Timeline

Drugs

Indications